Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Company Deals

Danaher to Acquire Masimo for $9.9B – Expands Diagnostics Platform with Pulse Oximetry Leader

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA Approves 76 Innovative Medical Devices in 2025 – 17% YoY Growth Driven by AI and Priority Review Surge

Fineline Cube Feb 26, 2026
Company Drug

Gan & Lee’s Insulin Biosimilars Win CHMP Positive Opinion – Bysumlog and Dazparda Near EU Market Entry

Fineline Cube Feb 27, 2026
Company Drug

Kanghong Pharma’s Orexin Antagonist KHN707 Cleared for Insomnia Trials – First-in-Class Sleep Disorder Candidate

Fineline Cube Feb 27, 2026
Company Drug

Duality Biologics Initiates Global Clinical Trial for DB-1419 in Advanced Solid Tumors

Fineline Cube Sep 11, 2024

Duality Biologics, Inc., a biopharmaceutical company based in China, has reached a significant milestone with...

Company Medical Device

Medtronic Secures China Market Approval for Pulsed Electric Field Atrial Fibrillation Treatment Devices

Fineline Cube Sep 11, 2024

Medtronic (NYSE: MDT), the US-Irish medical technology giant, has announced that it has received approvals...

Company Drug Legal / IP

AbbVie Accuses BeiGene of Trade Secret Theft in BTK Degrader Dispute

Fineline Cube Sep 11, 2024

AbbVie Sues BeiGene Over Alleged Trade Secret Theft in BTK Degrader ProgramU.S. pharmaceutical titan AbbVie...

Company Drug

Terns Pharmaceuticals’ Oral GLP-1R Agonist TERN-601 Shows Promising Weight Loss Results in Phase I Trial

Fineline Cube Sep 10, 2024

Terns Pharmaceuticals Inc. (NASDAQ: TERN), a U.S.-based biotechnology company originally spun out from Eli Lilly’s...

Company Drug

GSK’s Nucala Shows Promise in Phase III COPD Trial, MATINEE Results Positive

Fineline Cube Sep 10, 2024

GSK plc (LON: GSK, NYSE: GSK), a leading UK-based pharmaceutical company, has announced positive results...

Company Legal / IP

US House Approves Biosecure Act with Implications for Chinese Biotech Firms

Fineline Cube Sep 10, 2024

The US House of Representatives has taken a decisive step towards tightening biosecurity measures, voting...

Company Drug

CIRC’s Subsidiary HTA Co., Ltd. Secures NMPA Approval for Sodium Fluoride [18F] for Bone Imaging

Fineline Cube Sep 10, 2024

China Isotope & Radiation Corporation’s (CIRC) subsidiary, HTA Co., Ltd. (HKG: 1763), has announced that...

Company Drug

Fosun Pharmaceutical’s Daxxify Receives NMPA Approval for Aesthetic Use in China

Fineline Cube Sep 10, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...

Company Deals

Beijing Centergate Technologies and Bestcomm Pharmaceutical Form Strategic Partnership in Multiple Medical Fields

Fineline Cube Sep 10, 2024

Beijing Centergate Technologies (Holding) Co., Ltd (CENTEK, SHE: 000931), a pharmaceutical manufacturing company in China,...

Company Drug

Jiangsu Hengrui’s ANGPTL3 Inhibitor SHR-1918 Earns Breakthrough Designation for HoFH Treatment

Fineline Cube Sep 10, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Deals

Chengdu Kanghua Biological Products Inks Five-Year Partnership to Boost Sichuan’s Biotech and Vaccine Industries

Fineline Cube Sep 10, 2024

Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has...

Company Deals

JHM Biopharma Secures Over USD 28 Million in Series B+ Financing to Boost Pipeline Development

Fineline Cube Sep 10, 2024

JHM Biopharma, a protein drug developer based in Hangzhou, has reportedly secured over RMB 200...

Company Medical Device

Amoy Diagnostics’ AiHuiJie Lung Cancer Companion Diagnostic Receives NMPA Approval

Fineline Cube Sep 10, 2024

Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685), a biopharmaceutical company based in China, has announced...

Company Drug

AstraZeneca and Daiichi Sankyo’s Dato-DXd Misses Overall Survival Endpoint but Shows Promise in NSCLC Subgroup

Fineline Cube Sep 10, 2024

AstraZeneca (NASDAQ: AZN) and its co-development partner, Japan’s Daiichi Sankyo, have released data from the...

Company Deals

Candel Therapeutics Acquires Bispecific Antibodies and Secures $370 Million in Financing for Autoimmune Drug Development

Fineline Cube Sep 10, 2024

Candel Therapeutics, Inc. (CADL), a U.S.-based biopharmaceutical company, has announced the acquisition of two U.S....

Company Drug

Vcanbio’s Stem Cell Therapy VUM02 Gets NMPA Approval for Systemic Sclerosis Clinical Trial

Fineline Cube Sep 10, 2024

Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645), a biotechnology company based in China,...

Company Deals

Insilico Medicine Partners with Inimmune Corporation to Utilize AI for Immunotherapy Innovation

Fineline Cube Sep 10, 2024

Insilico Medicine, a leading artificial intelligence-driven drug discovery company based in China, has announced a...

Policy / Regulatory

NHC Releases Updated List of Pediatric Drugs for Research and Development Incentives

Fineline Cube Sep 10, 2024

The National Health Commission (NHC) has issued a notification regarding the fifth batch of pediatric...

Company Drug

Innovent Biologics’ Dupert Demonstrates Positive Results in Phase II NSCLC Trial

Fineline Cube Sep 10, 2024

Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...

Drug Policy / Regulatory

China’s CDE Issues Draft Guidelines for Biosimilar Pharmaceutical Similarity Research

Fineline Cube Sep 10, 2024

The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has released...

Posts pagination

1 … 261 262 263 … 627

Recent updates

  • Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars
  • Zai Lab Reports $457M Full‑Year Revenue – 16% Growth Driven by Xacduro and Nuzyra Expansion
  • Gan & Lee’s Insulin Biosimilars Win CHMP Positive Opinion – Bysumlog and Dazparda Near EU Market Entry
  • Kanghong Pharma’s Orexin Antagonist KHN707 Cleared for Insomnia Trials – First-in-Class Sleep Disorder Candidate
  • Akeso’s Manfidokimab NDA Accepted by NMPA – Anti-IL-4Rα mAb Targets Moderate-to-Severe Atopic Dermatitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Company

Zai Lab Reports $457M Full‑Year Revenue – 16% Growth Driven by Xacduro and Nuzyra Expansion

Company Drug

Gan & Lee’s Insulin Biosimilars Win CHMP Positive Opinion – Bysumlog and Dazparda Near EU Market Entry

Company Drug

Kanghong Pharma’s Orexin Antagonist KHN707 Cleared for Insomnia Trials – First-in-Class Sleep Disorder Candidate

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.